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QUALITY OF LIFE AND DEPRESSIVE SYMPTOMS AS PREDICTORS OF 
PARTICIPANT ADHERENCE IN A RANDOMIZED TRIAL CONDUCTED 
AMONG OLDER ADULTS AT RISK OF MOBILITY DISABILITY  
HAO ZHU 
ABSTRACT 
Poor adherence is an issue in clinical trials with a striking magnitude and 
negative impact. Recent studies indicate that two widely used clinical screening 
tools, Short Form (SF-36) Health Survey and Center for Epidemiologic Studies 
Depression Scale (CES-D) can be used as risk stratifiers to identify participants 
who require extra interaction to stay adherent in specific population. There is, 
however, little evidence to support the implication of these tools in elderly 
individuals with mobility limitations. These individuals may be particularly 
vulnerable to the risks of poor adherence in the context of a demanding 
interventional scheme. This study fulfills this gap by analyzing the quality of life 
and adherence data from the VIVE2 study, which is a double-blinded randomized 
explanatory clinical trial assessing the benefits of nutritional supplements and 
daily exercises to elderly patients with mobility limitation. The preliminary results 
showed that in clinical studies targeting elderly population with mobility limitations, 
the summary scores of SF-36 trended to have weak and nonsignificant 
association with a decreased risk of poor adherence to both exercise completion 
and product consumption while CES-D has no association.   
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INTRODUCTION 
Participant adherence, or compliance, is an important determinant of the 
outcome of both clinical practices and clinical trials. In the context of delivery of 
medical care, a 2003 World Health Organization (WHO) guidebook gave the 
definition of adherence as “the extent to which a person’s behavior – taking 
medication, following a diet, and /or executing lifestyle changes, corresponds 
with the agreed recommendations from a health care provider”1. In clinical 
research, the related concept of adherence describes the extent to which a 
subject’s behavior corresponds with what is anticipated by the consented study 
protocol. As discussed below, a high rate of participant adherence to the 
consented protocol is essential in generating valid research findings. This thesis 
uses an analysis of a randomized clinical trial (RCT) to investigate the hypothesis 
that in the context of a complex illness (loss of physical functioning), generalized 
measures of quality of life and participant well-being will be predictive of 
adherence to a demanding intervention schedule.  
The Importance of Participant Adherence to Clinical Research 
In ideal cases, a good clinical study should be built on a trust relationship 
between investigators and subjects. After subjects are well consented about the 
procedure, risks and benefits of the study, they are expected to strictly follow the 
study protocol. In practice, however, cases of poor adherence are widely found in 
the field of clinical research. In fact, reports have demonstrated that the 
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adherence rates in clinical trials ranges from 43% to 78% among subjects 
receiving treatments for different chronic diseases2. A few reviews also reported 
that in developed countries, the adherence rates in patients treated for chronic 
diseases are around 50%3, while in developing countries, the rates might be 
even lower due to the poor availability and accessibility of healthcare resources1. 
It is clear, therefore, that poor adherence can jeopardize the validity of clinical 
research in any setting.  
In clinical trials, poor adherence may be a critical problem because it may 
reduce the statistical power of the study, increase its cost, and may have grave 
implications for the applicability of its conclusions to the background population. 
When subjects are not compliant, the benefits of intervention might be 
underdetermined and the risks poorly understood. If the overall adherence rates 
in a study were very low, it would be reasonable to question whether the 
conclusion of the study were in any way useful or applicable outside the confines 
of the study itself. There are also ethical implications, because if a clinical study 
cannot produce valuable knowledge, the risks taken by subjects were probably 
wasted for no reason4.  
Factors thought to influence Adherence 
Due to the striking magnitude of poor adherence and its negative impact 
on clinical research, in the past decades, many studies have investigated the 
inner mechanism of non-compliant behaviors. Before the 1990s, most of the 
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studies were focused on the association between adherence and patients’ 
personality traits5,6. The results, however, were not consistent and sometimes 
contradictory. Since then, it has been recognized that adherence is actually a 
very complex behavioral process determined by several interacting factors1. 
These factors include characteristics of the disease, characteristics of the 
therapy, attributes of the patient and the patient’s environment.  
A systematic analysis in 2008 reviewed 102 cases from 2095 related 
articles and categorized all the potential risk factors for nonadherence into two 
groups: “hard” factors and “soft” factors7. Hard factors tend to be related and 
difficult to change, either necessary complexities of the intervention or system-
level obstacles or difficulties. These include therapy-related factors 
(administration methods, duration and side effects), healthcare system problems 
(accessibility and satisfaction), disease characteristics and healthcare 
expenditures. Generally, subjects trend to avoid following the therapy when the 
administration methods are complicated, the duration is long, or the side effects 
are noticeable. Their adherence rates will increase as the accessibility and 
satisfaction of healthcare system increases or the cost of the therapy decreases. 
Patients with a more severe disease also tend to have a higher rate of adherence. 
These hard factors are quantifiable but are relatively static. It is true that 
problems in healthcare system are amenable to study and improvement with 
great investment of resources. Increasing the accessibility and satisfaction of 
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healthcare system, however, requires a long time commitment and a strong 
social support. As a result, most of these hard factors are not easy to be 
amenable to management in clinical trials. 
The soft factors are the subject-level obstacles that may be realistically 
(relatively speaking) accommodated or, perhaps, improved in the context of a 
clinical study. These include subjects’ demographic factors, psycho-social factors 
such as subjects’ beliefs, attitude (depression, anxiety, fears or anger about the 
illness) and their motivation for therapy. Studies have found that females, the 
individual’s increased levels of education, and marital status are positively 
associated with a greater adherence to intervention protocols7. In younger 
populations, age is inversely related to adherence, whereas in older populations, 
age tends to be associated with a higher rate of adherence7. Regarding subjects’ 
psycho-social factors, it was reported that subjects’ beliefs about the causes and 
meaning of illness, and motivation to follow the therapy were strongly positively 
related to their adherence rates8–13. It also has been found that in elderly 
populations, major depression or anxiety was associated with a higher risk of 
poor adherence14. As compared with “hard factors,” these soft factors may be 
more meaningful for assessment in a clinical trial as they are more likely to vary 
from participant to participant and the information about most of these factors are 
usually collected at the baseline part of the studies. It may be useful, therefore, to 
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consider these factors as potential risk stratifiers for nonadherence within a 
particular trial. 
Rationale for Prediction of Poor Adherence at Trial Baseline 
An important lesson learnt over the past 40 years is that poor adhering 
subjects need to be supported by investigators to achieve the best results1. After 
cases of poor adherence occurred, it would never be a good solution to “blame” 
participants for nonadherence behavior. Blaming will not help fix the bad data but 
actually damages the subject-investigator relationship and makes the subjects 
become less likely to be compliant in the future15,16. One of the most powerful 
methods found to increase adherence rates is the good interaction and 
communication between investigators and subjects15,17. Thus, in clinical research, 
investigators should take the responsibility of keeping subjects from poor 
adherence by providing adequate education before study starts and maintaining 
good communications with subjects during the study. 
Perhaps the biggest challenge of doing clinical research is that the 
resources are often severely limited. It is easy to set a goal that investigators 
should have substantial direct communications with subjects throughout the 
study. In many cases, however, it is very hard to achieve this goal, especially 
when the sample population is large. It is difficult for investigator to direct 
attention to all each individual participant, and needless to say there are some 
participants who require additional attention to stay compliant. As a result, there 
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is a need of to better identify sub-groups of participants with a higher risk of poor 
adherence at the beginning of the study. Then, the study investigators can have 
an opportunity to better support them throughout the intervention period. 
Rationale for Choice of Quality of Life as potential risk-stratifier on Poor 
Adherence 
For a useful baseline measure to predict risks of poor adherence in clinical 
research, we propose the following requirements: 
• The measure should be widely applied and available; 
• The measure should broadly incorporate the patient related risk factors for 
poor adherence described above;  
• The measure must be feasibly deployable at baseline of a clinical 
research study. 
Limited research suggests that it is possible to use the Short Form (SF-36) 
Health Survey18, which measures health-related quality of life (HRQOL), and the 
Center for Epidemiologic Studies Depression Scale (CES-D)19, which measures 
the presence of depressive symptomatology, as tools to predict poor adherence. 
A study conducted in 2011 found that the SF-36 measures were significantly 
associated with decreased adherence among urban African Americans with 
severe, poorly controlled hypertension20. Another study, which evaluated 
hazardous alcohol use and depressive symptomatology among HIV-infected 
patients in Nigeria, reported that an elevated CES-D score is associated with 
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decreased adherence as well21. Below we give a brief overview of these 
assessments.  
The SF-36 test is a well-validated short-form health survey intended to 
evaluate physical/mental health and general well-being [citation for SF-36 design]. 
It consists of 36 questions and generates an 8-subscale profile, which includes 
vitality (VT), physical functioning (PF), bodily pain (BP), general health 
perceptions (GH), physical role functioning (RP), emotional role functioning (RE), 
social role functioning (SF) and mental health (MH). Questions in these 8 
subscales can be reorganized into two categories: Physical Component 
Summary (PCS) and Mental Component Summary (MCS). All of these subscales 
and component summaries can be evaluated independently for different 
purposes. Due to its high accuracy and flexibility, SF-36 became a popular 
general clinical instruments for many purposes, since it was first developed in 
199218. It has been translated into more than 170 languages and is widely used 
around the world22.  
The CES-D scale is a screening assessment for major depression and 
depressive disorders, which is widely used in clinical research as an indicator of 
the presence and severity of depressive symptoms. It consists of 20 questions 
assessing the 9 symptoms of depression, including sadness (dysphoria), loss of 
interest (anhedonia), iregular appetite, decreased sleep quality, difficulties in 
thinking and concentration, feelings of guilt or lack of self-worth, excessive 
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tiredness (fatigue), increased undirected movement (agitation) and suicidal 
ideation. The CES-D scale is one of the most widely used medical instrument in 
the field of psychiatric epidemiology, and is commonly employed in aging 
research and in other disciplines23.  
Both SF-36 and CES-D tests are commonly used as baseline tests in 
clinical trials, address in broad terms the patient-related factors of poor 
adherence discussed above, and can be readily administered at the start of a 
research study. These therefore meet our broad criteria for eligible risk stratifies. 
As noted above, there currently exist only a few studies assessing the feasibility 
of using these two tests as predictors of poor adherence and most of these 
studies are focusing on specific populations, and none of these have addressed 
physical function as an outcome. There are still large amounts of knowledge 
about the implication of these methods in many other different populations 
waiting to be explored.  
Adherence and Aging  
An unexplored population is the seniors. Even though many studies have 
found that in elderly populations, age is associated with a slightly higher 
adherence rates7, it is undeniable that certain subgroups of older subjects are 
more vulnerable to some barriers to adherence1. Examples of such subgroups 
include subjects with multiple chronic diseases or multi-morbidity, subjects with 
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memory difficulties and subjects with mobility limitations. The latter are the target 
population of the analyses reported here.  
Importantly, many elderly subject have multiple chronic diseases. As a 
result, they are usually recommended to take multiple medications together with 
the study medication simultaneously. It has been found that this excess burden 
of medications – or polypharmacy - may confuse subjects, especially when 
subjects are required to take these medications multiple times a day24. Multiple 
medications increase the risk of missing medications, dosing errors, and drug 
interactions, and therefore might conceivably increase the risks of poor 
adherence in an RCT.  
Also, mobility limitation, which is one of the most common health issues 
among elder subjects, is another important factor to consider for elderly subjects 
at risk of poor adherence. Mobility limitations prevent elderly subjects from 
coming to clinical visits or prevent them from coming to visits on time1. First of all, 
it increases the chance of getting missing data. At the same time, it decreases 
the chance for subjects to communicate and build close bonds with investigators, 
which have been proven to be one of the significant determinants of poor 
adherence. Thus, elderly subjects in clinical research need particular attention in 
clinical management to maintain compliant in clinical trials.  
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Background of Mobility Disability in Elderly Population 
Mobility limitation and loss of functional ability in aging are predictive of 
decreased quality of life, disability and premature mortality. They are also 
associated with greater resource utilization and increased health care costs25–28. 
It is therefore critically important to prevent loss of mobility in aging, and 
numerous interventions including physical activity, resistance training, mind/body 
exercise, nutritional or behavioral adaptations, pharmacologic agents and other 
interventions are currently the focus of testing as function-promoting therapies 
and for the prevention of injury29–33. The project described here is one of such 
interventions. 
Limited Evidences in Elderly Subjects at Risk of Mobility Disability 
As discussed above, elderly subjects with mobility limitations are among 
the subgroups of elderly population at larger risks of poor adherence. Currently, 
however, there are only very limited number of studies focusing on adherence in 
this population34–38. A good example of such studies is the Lifestyle Interventions 
and Independence for Elders Pilot (LIFE-P) study. LIFE-P study is a well-
organized, 12-month clinical trial designed to compare the effects of physical 
activity intervention (PA) and a health education control on risk of disability in 
elderly population33. According to this study, adherence to physical activity is 
associated with a higher Short Physical Performance Battery (SPPB) score38, 
which is a validated indicator of a better general mobility and physical 
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functioning39. This finding confirms the important role of physical activity 
adherence for elderly people to maintain a good mobility.  
A secondary analysis of the LIFE-P study in 2007 also tried to address the 
predictors of adherence to physical activity in this study34.  To my knowledge, this 
is the only study assessing the predictors of adherence in the elderly population 
with mobility limitations. The results of this analysis indicated that baseline 
demographic variables, disease burden, self-reported symptoms, physical 
functioning and social cognitive variables could predict 10% of the variance in the 
adherence rate during intervention. If the adherence rate during the baseline test 
is also considered inside this model, the amount of explained variance increased 
from 10% to 21%. The investigators also report that the associations were not 
very consistent as different phases of the study, which indicated risks of poor 
adherence, might change with time.  
Thus, currently, regarding the purpose of validate the use of baseline SF-
36 and CES-D scores as clinical instruments to predict subject adherence during 
the study for elderly subject with mobility limitations, the existing scientific 
evidences are very limited. As a result, we conduct this study using data from the 
VIVE2 study, a recent clinical trial addressing the mobility issues in elders, to 
fulfill this need.  
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The VIVE2 Study 
The “Efficacy of Nutritional Supplementation on Physical-activity Mediated 
Changes in Physical Functioning Older Adults at Risk for Mobility Disability” (or 
VIVE2) study is a randomized, multi-centered (U.S. and Sweden), double-blind 
clinical trial that compares the effects of a 6 month (28 weeks) structured 
physical activity program with a daily nutritional supplement (NESTLÉ® “Senior 
II”) or placebo on changes in functional limitations in older adults aged ≥70 years 
with mobility limitations. The primary outcome is the difference between the 
walking speed of a 400 M walk at baseline and that after 6 months. Other 
outcomes include the functional limitations (3 month 400 M walking speed vs that 
at baseline, Stair climb, and SPPB score), body composition (Dual Energy X-Ray 
Absorptiometry (DXA) and Computed Tomography (CT)), peak torque and power 
measure, nutritional status (Mini Nutrition Assessment Short Form (MNA-SF), 
quality of life (SF-36) and depressive symptoms (CES-D).  
The primary analytic goal for the VIVE2 study is to assess whether the 
nutritional intervention can out-perform placebo in producing exercise-induced 
changes in physical function. The sub-study described here utilizes the VIVE2 
study database to assess evidence of association between quality of life and 
adherence to intervention, without regard to randomization. Per the VIVE2 
protocol, a participant is classified as “Poor adherent” if (s)he participates in 
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fewer than 60% of planned interactions per protocol over the 24-week 
intervention period.  
 
Study Objectives 
Primary Objectives 
The primary objectives of this study are to assess whether the baseline 
physical and mental SF-36 summary scores (PCS & MCS) and CES-D scale are 
associated with the odds of being classified as “Poor adherent” in an elderly 
population with mobility limitations. Based on past literature20,21, we hypothesized 
that a higher baseline PCS score of the SF-36 test would be associated with an 
increased higher odds of being  “Poor adherent,” while the MCS score of the SF-
36 test probably would have no such association. We also hypothesized that 
baseline level of depressive symptoms (assessed by CES-D Scale) would be 
probably positively associated with the odd of being “Poor adherent”.  
Because all participants in the VIVE2 study receive a structured exercise 
program (the same regardless of randomization), and each receives (according 
to randomization) either a nutritional intervention or placebo, the project 
described here considers both the exercise and nutritional interventions in 
independent analyses.  As noted above, the threshold of 60% adherence applies 
to both the exercise and nutritional activities, independently.  
14 
 
Secondary Objectives 
Analysis of “proportionate” adherence 
Instead of being counted as a binary (“Good adherent”/”Poor 
adherent”) variable, poor adherence will also be analyzed as a quantitative 
variable to provide more information about the effects of the baseline tests’ 
scores on the probability of a non-adhering event to occur. For the 
purposes of this analysis, the adherence outcome is computed as the 
simple proportion of planned activities completed by the participant, with 
exercise and nutritional components again treated individually. 
SF-36 Subscale Score Analyses 
Similarly, the association of each SF-36 subscale (PF, RP, BP, GH, 
VT, SF, RE and MH) and poor adherence will be analyzed. 
Multiple Regression Model of Poor Adherence 
Finally, a risk-prediction model for poor adherence will be 
developed taking into account other factors including age, sex and other 
demographic factors and baseline measures. 
Summary 
Poor adherence is an issue in clinical trials with a striking magnitude and 
negative impact. Past research indicates the only way to solve this issue is to 
provide study participants more supports, rather than placing responsibility on 
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them alone. In principle, the use of standard surveys as potential risk stratifiers of 
poor adherence may help in anticipating the subgroups of subjects at greatest 
need of additional attention at little to no additional cost of detection. 
Investigators might then use the limited resources available to them to better 
support participants who require extra interaction to stay compliant. Recent 
studies indicate that SF-36 and CES-D are reasonable candidates in specific 
populations, but there is little existing evidence to support the implication of these 
tools in elderly individuals with mobility limitations, who may be particularly 
vulnerable to the risks of poor adherence in the context of a demanding 
interventional scheme. This study will address this gap by analyzing quality of life 
and adherence data from the VIVE2 study, which is a double-blinded randomized 
clinical trial assessing the benefits of nutritional supplements and daily exercises 
to elderly patients with mobility limitation.  
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METHODS 
Overview of the VIVE2 Study 
In this study, 150 subjects aged 70 years or older at risk of mobility 
disability were randomized to receive daily either the nutritional supplement 
(NESTLÉ® “Senior II”) or a placebo for a period of 6 months. During the study, all 
participants were also required to take a 3-time per week multi-model physical 
activity training program (strength, balance and stretching). Clinical measures 
were taken at the baseline, 3 month visit and 6 months visit.  
Study Product Description 
The nutritional supplement used in this study, NESTLÉ® “Senior II”, is a 
119 mL (4 Oz) nutritional beverage. The formulas consist of 20 g high quality 
whey protein, 800 IV vitamin D, and 350 mg Ca. It can provide 150 kcal of energy 
with 6.5 g carbohydrate, and 6 g lipids. The placebo was a sweetened and 
flavored beverage serving at a size of 119 mL with 20-30 calories. The packages 
of the nutritional supplement and the placebo were identical.  
Physical Activity Program Description 
Subjects in both intervention arm and placebo arm were also required to 
participate in a multi-model physical exercise program specifically designed by 
Tufts University and Nestlé. The purpose of this activity program was to introduce 
subjects to the strength, stretching, and balance portions of the program in a safe 
and effective manner. These center-based exercise instruction sessions were 
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hosted three times per week and were supervised by nurses and investigators. 
The exercise duration was approximately one hour which included a warm-up 
period, 30 minutes of aerobics, 20 minutes of strength exercises (using ankle 
weights), and a cool down period. The warm-up and cool down sessions included 
flexibility and balance exercises. The subject attendances were recorded down 
and were used to evaluate the adherence level in the study.  
At the same time, subjects were encouraged to conduct physical activity 
trainings outside of class. Investigators also provided them with instructions on 
taking records of any physical activities (strengthening, stretching and balancing) 
done out of class.  
Screening, Randomization and Blinding Protocols 
A total of 154 subjects were screened for the eligibility to participate in this 
study and 150 subjects qualified (84 at Tufts University, Boston, MA, United 
States and 66 at Uppsala University and Karolinska Institutet, Stockholm, 
Sweden). Subjects were subsequently randomized into two arms but four groups 
(two groups in each arm) in order to increase the level of blindness in this study. 
During the study, the combination codes of the randomization groups were only 
known by the manufacturer (NESTLÉ PTC Konolfingen, Switzerland) and will not 
be revealed to investigators until the final version of the statistical analysis plan 
(SAP) is approved and the definition of intention to treat (ITT) analyses and per-
protocol (PP) analyses are finalized.  For the purposes of analyses described 
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here, randomization is not considered as a factor in adherence; all participants 
are considered in a unified analysis. 
Inclusion and Exclusion Criteria for the VIVE2 Study 
Inclusion and exclusion criteria are described at length in Appendix I. 
Briefly, participants are community-dwelling men and women of at least 70 years 
of age who are willing to be randomized and participate in the exercise 
intervention. They are generally free of major comorbidities including recent 
major cardiovascular events, major recent surgeries, insulin-dependent diabetes 
mellitus, cancers and terminal illnesses, but are at risk of mobility limitation as 
indicated by an SPPB score of no greater than 9.   
 
Measures 
SF-36 Measures 
The SF-36 measures were taken at the baseline, 3 months visit and 6 
months visit. This survey consists of 36 questions evaluating 8 subscales of the 
general wellbeing. In the end, questions can be recombined into physical 
component summary (PCS) and mental component summary (MCS) as shown in 
Table 1.  All these subscales and summary scores can be used as independent 
variables to predict poor adherence in this study. In addition, at the Swedish sites, 
a translated version of the SF-36 questionnaire was used40,41. The Swedish 
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version of SF-36 was using a different scaling system but could be normalized 
through a validated process41.  
TABLE I. Components of SF-36 Tests 
Summarie
s 
Subscales Items 
Ph
ys
ica
l C
o
m
po
n
e
n
t S
u
m
m
ar
y 
 
Physical Functioning 
(PF) 
3. Vigorous Activities 8. Bend, kneel 
4. Moderate Activities 9. Walk mile 
5. Lift, carry groceries 10. Walk several 
blocks 
6. Climb several flights 11. Walk one block 
7. Climb one flight 12. Bathe, dress 
Role-Physical (RP) 13. Cut down Time 15. Limited in kind 14. Accomplished less 16. Had difficulty 
Bodily Pain (BP) 21. Pain-magnitude 22. Pain-interfere 
M
e
n
ta
l C
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n
e
n
t S
u
m
m
a
ry
 
General Health (GH) 
1. General health 
rating 
35. Health worse 
33. Sick easier 36. Excellent 
34. As healthy as 
anyone 
 
Vitality (VT) 23. Pep/life 29. Worn out 27. Energy 31. Tired 
 Social Functioning (SF) 20. Social-time 32. Social-extent 
Role-Emotional (RE) 17. Cut down time 19. Not careful 18. Accomplished less  
Mental Health (MH) 
24. Nervous 28. Blue/Sad 
25. Down in dumps 30. Happy 
26. Peaceful  
 
CES-D Measures 
In addition to the SF-36 test, the CES-D scale was also given at the 
baseline, 3 month visit and 6 month visit. This scale consists of 20 questions 
asking subjects to rate the frequencies of certain emotions, such as loneliness 
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and sadness, over the last week at a scale from 0 to 3 (in most cases, 0 = rarely, 
1 = some or little of the Time, 2 = moderately or much of the time, 3 = most or 
almost all the time). The total score ranges from 0 to 60 and a higher score is 
associated with greater depressive symptoms19. The cutoff CES-D score that aid 
in identifying individuals at risk for clinical depression, with good sensitivity and 
specificity, was 1642.  
400 M Walk Measures 
Average walking speed during a 400 M walk test is the primary outcome of 
the VIVE2 study. This test was also given at the baseline, 3 month visit and 6 
month visit. For this study, baseline walking speed and other functional measures 
are used only for descriptive purposes. Subjects were asked to walk at their 
normal speed for 10 laps around a 40 meter course, or until they could no longer 
continue. They were not allowed to walk with the help of an assistive device, 
such as canes and walkers, or the help of other people. If a subject didn’t finish 
the 400 M walk, the average speed was still calculated and used in the analysis 
based on the distance the participant traveled and the time spent. 
Nutritional Intervention Adherence 
During the study, subjects were required to drink the nutritional 
supplement/placebo every day during a 180-day period. During the three 
physical activity sessions in a week, subjects were asked to take the drink after 
the session with the supervision of investigators. During the remaining four days 
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of the week, subjects were asked to take record down whether they had taken 
the drinks on a provided log sheet. The supervised intakes and the self-
administrating intakes were treated equally in the analyses presented here.   
Exercise Program Adherence 
As discussed above, subjects were required to participate on a 3-day a 
week physical activity program. Their attendance was recorded down by study 
nurses and the records were used to evaluate adherence. As with the nutritional 
records, subjects were instructed to record down the daily completion of the 3-
portion exercise (strength, stretching and balance) during the rest of the week on 
a provided log sheet.  
Definition of Risk of Poor Adherence  
In the statistical analysis of this study, poor adherence was evaluated 
either as a continuous variable, or as a discrete variable. First, the overall risk of 
exercise/product nonadherence for each subject was calculated based the 
reported daily completion of exercise activities or product consumptions. This 
variable was a continuous number which evaluated the probability of non-
adhering events to occur.  
Then, based on the Statistical Analysis Plan (SAP) of the VIVE2 study, the 
per-protocol analysis would exclude subjects who completed less than 60% of 
planned exercise activities or 60% of the nutritional supplements. It means that 
when subjects’ risks of non-adherence were smaller than or equal to 40%, they 
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would be classified as “Good-adherent” but when the risks increased over 40%, 
they would be classified as “Poor-adherent”. The mathematical equation for this 
process is described as below. 
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Statistical Analysis Plan 
Primary Analysis 
The primary analysis of this study was to assess the association between 
participants’ baseline scores on SF-36 and CES-D tests and adherence to 
planned exercise and nutritional activities. Poor adherents were defined as 
subjects who completed less than 60% of the assigned exercises and product 
consumption, independently. Since the test scores are numerical while the 
primary outcome is a binary variable, the associations were examined by 
multivariate logistic regression. A total of four multivariate models were 
constructed. The first one was a simple model only adjusted by study location 
and the second one was adjusted by study, location, age, and sex. Model 3 
adjusted study location, age, sex, and 400 M walking speed and Model 4 
adjusted all the factors in model 3 plus BMI, vitamin D level models, and Mini-
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Nutrition Assessment Short Form (MNA-SF) as nutrition were found to be 
important factors to mobility in elderly population43. 
Secondary Analyses 
Risk of Poor Adherence (continuous) Analysis 
Following the primary analysis, the first secondary analysis was to 
assess the effects of baseline tests’ scores on the overall probability of 
non-adhering events to occur. In this case, all of the variables, including 
the outcome, are continuous variables. As a result, the associations were 
examined using linear regression analysis. Similarly, four multivariate 
models were built and adjusted by the same factors in the primary 
analysis.  
SF-36 Subscale Score Analyses  
We also investigated the association between each SF-36 subscale 
score (PF, RP, BP, GH, VT, SF, RE, and MH) and the odds of poor 
adherence by building a multiple logistic regression models considering 
each of the 8 subscores independently, along with study site. 
Risk-prediction Model for Poor Adherence 
Finally, all of these factors were considered in risk-prediction 
models for poor adherence. This consisted of multiple logistic regression 
models considering the 8 subscales of SF-36 and the CES-D score, with 
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control for age, sex, study center, BMI, vitamin D level, MNA-SF score, 
400 M walking speed, and SPPB score.   
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RESULTS 
Description of trial sample 
Baseline characteristics for the 150 participants in the VIVE2 study are 
shown in Table II; baseline characteristics stratified by randomization groups are 
listed in Table A.1 in Appendix II. In this study, the subject’s age ranged from 69 
to 100 years and have a sample mean ± standard deviation (SD) age of 78 ± 5 
years. About 54% of the participants were male. This percentage is higher than 
the national average (41%) in the United States in 201044.    
TABLE II. Baseline Overall Descriptive Characteristics (N=150) 
Demographics    
Age, yr  78 (5) BMI, kg/m2  28.2 (3.6) 
Men (N, %) 81 (54%) Vitamin D, nmol/L  42.7 (9.7) 
US site (N, %) 84 (56%)   
Baseline Tests 
Scores 
   
MNA-SF Score 13.3 (1.2) 400 M Speed, m/s 0.91 (0.16) 
SF-36 Scores    
SF-36 Summary 
Scores 
   
PCS 45.7 (8.6) MCS 51.6 (9.3) 
SF-36 Subscale 
Scores 
   
Vitality 61.5 (18.5) Role-physical  64.1 (33.5) 
Physical Functioning  67.2 (19.7) Role-emotional  72.6 (31.0) 
Bodily Pain  68.9 (22.6) Social Functioning  83.3 (20.9) 
General Health 67.1 (17.4) Mental Health  77.8 (16.7) 
CES-D Score 11.6 (7.2)   
Abbreviation: BMI, body mass index; MNA-SF, Mini Nutritional 
Assessment Short-Form; SF-36, Short Form Health Survey; PCS, 
Physical Component Summary; MCS, Mental Component Summary; 
CES-D, Center for Epidemiological Study Depression Scale.  
The average baseline BMI level was 28.2 ± 3.6 kg/m2, and most of the 
participants met a crude definition of “overweight” (BMI ≥ 25.0 kg/m2)45 at 
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baseline. The average 25(OH) vitamin D level was 42.7 ± 9.7 nmol/L and 76.2 % 
met the commonly used criterion for vitamin D insufficiency (25(OH) D < 50 
nmol/L)46. The baseline MNA-SF test indicated that most subjects had normal 
nutritional status because their test score dropped within the normal range of 12 
to 14 points47.  
In this study, the average PCS score of SF-36 test (45.7 ± 8.6) were below 
the 1998 national average but the average MCS score (51.6 ± 9.3) were above 
the average as the national averages for both PCS and MCS were normalized to 
50.0 ± 10.048. In addition, after normalization with the national average data, 5 
out of the 8 subscales, namely physical function, bodily pain, general health, role-
physical and role emotional were below national average. The other 3 subscale, 
including vitality, social functioning and mental health, were above national 
average. Most subjects did not meet the most commonly used criterion for 
prevalent depressive symptoms (CES-D > 16).19   
Distribution of Adherence statistics  
Center-specific distributions of adherence are depicted in Figure 1. A total 
of 12% of individuals met the criterion for poor adherence with the exercise 
program. Adherence to the nutritional intervention was higher, with only 3% of 
individuals meeting the criterion for nutrition non adherence. The mean ± SD 
proportion of visits at which participants were non-adherent for exercise was 0.21 
± 0.14, as compared to 0.07 ± 0.09 for nutrition.  
  
Association of SF-36 
The results of the primary analysis 
trend is that both SF-36 summary scores were associated with a slightly lower 
risk of being categorized as exercise or product poor adherents while there 
seems to be no association between CES
Based on the fully adjusted Model 4, the 
Figure 1. Boxplots showing distribution of exercise non
According to the protocol, participants with 40% proportionate non
(above blue line) are considered noncompliant.
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and CES-D Scores with Poor Adherence
are presented in Table III
-D scores and odds of poor adherence. 
odds ratio for the association between 
-adherence score by site. 
 
 
. The general 
-adherence 
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PCS and poor exercise adherence was 0.91. In other words, for every one point 
positive difference in the PCS score, an individual has a model-estimated -9% 
multiplicative decrease in the odds of nonadherence (95% CI: -0.19 to 0.01). 
None of these findings were, however, statistically significant, likely due in part to 
the limited sample size.  
TABLE III. Multivariate Logistic Regression Models Demonstrating the Association of 
Baseline SF-36 and CES-D Scores with Poor Adherence among Subjects in the VIVE2 
Study 
 Model 1a 
OR (95% CI) 
Model 2b 
OR (95% CI) 
Model 3c 
OR (95% CI) 
Model 4d 
OR (95% CI) 
Poor Exercise Adherence 
PCS (SF-36) 0.93 (0.84-1.02) 0.93 (0.84-1.02) 0.92 (0.83-1.02) 0.91 (0.81-1.01) 
MCS (SF-36) 0.97 (0.87-1.07) 0.96 (0.87-1.06) 0.96 (0.86-1.06) 0.95 (0.84-1.07) 
CES-D 0.99 (0.86-1.12) 0.99 (0.86-1.12) 0.98 (0.85-1.12) 1.00 (0.85-1.19) 
Poor Product Adherence 
PCS (SF-36) 0.96 (0.83-1.14) 0.96 (0.82-1.13) 0.95 (0.81-1.13) 0.98 (0.82-1.16) 
MCS (SF-36) 0.98 (0.84-1.14) 0.98 (0.84-1.14) 0.98 (0.83-1.15) 0.95 (0.79-1.12) 
CES-D 0.99 (0.81-1.20) 1.00 (0.81-1.21) 0.99 (0.81-1.20) 1.00 (0.78-1.22) 
How to read the table: one point increase in the test scores would affect the odds of being 
categorized as Poor Adherence by a certain value. Abbreviations: OR, odds ratio; CI, 
confidence interval; PCS, physical component summary; MCS, mental component summary; 
SF-36, Short Form Health Survey; CES-D, Center for Epidemiologic Studies Depression Scale. 
a Model 1: associations between test scores and poor adherence adjusted only by study sites. b 
Model 2:  associations adjusted sites, age and sex. c Model 3: associations adjusted by sites, 
age, sex, and walking speed. d Model 4: associations adjusted by sites, age, sex, walking 
speed, BMI, vitamin D level models and MNA-SF score. 
 
Association of Test Scores with Continuous Measures of Nonadherence 
When non-adherence was quantified as a continuous outcome (see 
Methods), the findings generally agreed with the findings in the primary analysis. 
Overall, higher PCS and MCS scores were insignificantly associated with lower 
risks of non-adhering events in both exercise completion and nutrition. In addition, 
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all of the prediction models showed that CES-D was also insignificantly 
associated with a lower risk of exercise non-adhering events but seemed to have 
no association with the risk of product consumption non-adhering events.  
TABLE IV. Multivariate Linear Regression Models Demonstrating the Association of 
Baseline SF-36 and CES-D Scores with Risk of Nonadhering Events (%) among Subjects 
in the VIVE2 Study 
 Model 1a 
RR (95% CI) 
Model 2b 
RR (95% CI) 
Model 3c 
RR (95% CI) 
Model 4d 
RR (95% CI) 
Risks of Nonadhering Exercise Events to Occur (%) 
PCS (SF-36) 0.88 (0.59-1.31) 0.89 (0.60-1.33) 0.92 (0.60-1.41) 0.84 (0.54-1.29) 
MCS (SF-36) 0.98 (0.64-1.51) 0.97 (0.63-1.50) 0.96 (0.61-1.49) 0.92 (0.57-1.48) 
CES-D 0.92 (0.53-1.59) 0.91 (0.52-1.58) 0.86 (0.49-1.51) 0.86 (0.45-1.61) 
Risks of Nonadhering Product Consumption Events to Occur (%) 
PCS (SF-36) 0.84 (0.66-1.07) 0.87 (0.68-1.11) 0.85 (0.66-1.09) 0.85 (0.65-1.11) 
MCS (SF-36) 0.95 (0.76-1.20) 0.92 (0.73-1.16) 0.91 (0.72-1.15) 0.90 (0.70-1.17) 
CES-D 1.06 (0.80-1.41) 1.02 (0.76-1.35) 0.99 (0.74-1.33) 0.98 (0.71-1.36) 
How to read the table: one point increase in the test scores would affect the percentage risks of 
nonadhering events by a certain value. Abbreviations: RR, relative risk; CI, confidence interval; 
PCS, physical component summary; MCS, mental component summary; SF-36, Short Form 
Health Survey; CES-D, Center for Epidemiologic Studies Depression Scale. a Model 1: 
associations between test scores and poor adherence adjusted only by study sites. b Model 2:  
associations adjusted sites, age and sex. c Model 3: associations adjusted by sites, age, sex, 
and walking speed. d Model 4: associations adjusted by sites, age, sex, walking speed, BMI, 
vitamin D level models and MNA-SF score. 
 
Associations of SF-36 Subscales with Poor Adherence 
The SF-36 subscale analyses also reported no association or very weak 
association between each SF-36 subscale and the odds of poor adherence. In 
most cases, the odds ratios crossed 1 and the associated p values were large, 
which indicated relatively little evidence against the null hypothesis of no 
association. The only one significant association was found between physical 
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functioning and poor exercise adherence. Even in this case, the association was 
relatively week and the odds ratio was found to be 0.95. In other words, for every 
one point increase in the physical functioning scores (ranging from 0 to 100), an 
individual would have an estimated 5% lesser risk to being categorized as poor 
adherent.  
Table V. Associations between each SF-36 Subscale and Poor Adherence 
SF-36 Subscale Poor Exercise Adherence Poor Product Adherence 
OR 
(95%CI) 
P 
value 
OR 
(95%CI) 
P 
value 
Physical Functioning (PF) 0.95 (0.92-0.98) 0.01 1.00 (0.95-1.08) 0.88 
Role-physical (RP) 0.99 (0.97-1.01) 0.28 1.01 (0.97-1.05) 0.80 
Bodily Pain (BP) 1.00 (0.97-1.02) 0.56 0.97 (0.91-1.02) 0.24 
General Health (GH) 0.99 (0.96-1.03) 0.74 1.01 (0.95-1.09) 0.76 
Vitality (VT) 0.98 (0.94-1.01) 0.23 0.97 (0.91-1.04) 0.40 
Social Functioning (SF) 0.99 (0.96-1.02) 0.43 0.99 (0.94-1.05) 0.63 
Role-emotional (RE) 1.00 (0.98-1.02) 0.71 1.01 (0.97-1.07) 0.70 
Mental Health (MH) 0.99 (0.96-1.03) 0.53 1.00 (0.94-1.08) 0.93 
How to read the table: one point increase in the test scores would affect the odds of being 
categorized as Poor Adherence by a certain value. Abbreviations: OR, odds ratio; CI, 
confidence interval; SF-36, Short Form Health Survey. 
 
Risk Prediction Model for Poor Adherence 
Table VI below only demonstrates the factors affecting the risk of poor 
exercise adherence. (As noted in Figure 1, the product adherence rate in the 
VIVE2 study was very high. As a result, the fully adjusted model could not be 
built for risk of poor product adherence because the degrees of freedom were 
insufficient.) 
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Table VI. Multivariate Logistic Regression Model Assessing the Associations of Each 
SF-36 Subscale and Poor Adherencea  
 
Poor Exercise Adherence 
OR(95%CI) P value 
SF-36 Subscales   
Physical Functioning (PF) 0.93 (0.88-0.98) 0.01 
Role-physical (RP) 0.99 (0.96-1.01) 0.29 
Bodily Pain (BP) 1.00 (0.96-1.03) 0.93 
General Health (GH) 0.97 (0.91-1.03) 0.30 
Vitality (VT) 0.97 (0.92-1.02) 0.23 
Social Functioning (SF) 0.96 (0.91-1.01) 0.09 
Role-emotional (RE) 1.00 (0.98-1.03) 0.83 
Mental Health (MH) 0.92 (0.85-0.99) 0.03 
CES-D Score 1.04 (0.94-1.16) 0.45 
How to read the table: every one point increase in the test scores (for walking speed, every 
0.1 m/s increase) would affect the odds of being categorized as Poor Adherence by a certain 
value. Abbreviations: OR, odds ratio; CI, confidence interval; SF-36, Short Form Health 
Survey. aThis is a multivariate model adjusted by study sites, age, sex, 400 M walking speed, 
BMI, vitamin D level and MNA-SF score.  
In this model, physical functioning and mental health were found to be 
significantly associated with a decreased risk of being categorized as poor 
exercise adherents. Every one point cross-sectional increase in PF and MH 
would decrease the odds of poor exercise adherence by 7% and 8%. The other 6 
subscales of the SF-36 test and the CES-D test are found to have no association 
with poor adherence.  
Other Factors 
In a model that considered physical functioning, mental health, age, sex 
(female), study centers, BMI and MNA-SF, subjects completed the study in the 
United States were reported to be nearly 3 times (OR: 2.97, 95% CI: 0.64-15.69) 
likely to become poor adherents while females reduced the risk by 61% (OR: 
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0.39, 95% CI: 0.07-1.72). Both of these findings, however, were statistically 
nonsignificant. Other factors, including age, BMI and MNA-SF score were found 
to be irrelevant. The detailed values are shown in Table A2 in Appendix II.  
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DISCUSSION 
Interpretation of the Results 
This study examined the possible associations of baseline SF-36 and 
CES-D scores with the in-study risk of poor adherence. Generally, the 
associations were found to be relatively weak. In the primary analysis, all the four 
logistic regression models failed to provide statistically significant association but 
indicated a general trend that both PCS and MCS scores were associated a 
slightly lower risk of being categorized as poor adherents while CES-D score 
seemed to have no association.  
These findings did not agree with the study hypothesis, which was made 
based on literature review, intuition, and the results of a previous study20.  That 
study assessed the association between baseline SF-36 scores and risk of poor 
adherence among subjects with poorly controlled hypertension. It was reported 
PCS was significantly associated with an increased risk of poor adherence while 
MCS had no association with poor adherence. One of the possible explanations 
was that people with poorly controlled hypertension may have comparatively 
limited concerns with their mobility ability. As a result, physical functioning 
limitations might be less of a barrier for them to come to study sites and thus 
limiting their risk of becoming nonadhering due to physical limitations. By contrast, 
the subjects in the VIVE2 study were chosen specifically for risk of mobility 
disability. Occasional mobility issues, therefore, could become a reason why they 
could not present the assigned physical training sessions and increase the risk of 
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poor adherence. In this specific population, however, it would be reasonable that 
a high mobility ability, which was indicated by a higher PCS score, could predict 
a lower risk of poor adherence. Another possible explanation to the difference 
between the study finding and study hypothesis was that the hypertension study 
was conducted in Baltimore, MD, while the VIVE2 study was conducted in 
Boston, MA and Sweden. The location could play an important role here and 
affect the associations as many social-economic factors and health care policies, 
such as medical insurance policies, were different. 
Our secondary analyses also found that both physical functioning and 
mental health were significantly associated with a decreased risk of poor 
adherence. In fact, in the hypertension study, these two subscale scores were 
also the only two that had significant associations with risk of poor adherence. 
The difference was that the hypertension study reported that physical functioning 
score was positively associated with the risk. The hypothesized explanations to 
this difference should be the same as explained in the last paragraph. In addition, 
it should be noted that both studies reported that the mental health subscale in 
the SF-36 test was associated with a lower risk of poor adherence. In other word, 
when subjects were mentally healthy, they would have a larger chance to follow 
the study protocol.  
The negative association of generalized mental health and risk of poor 
adherence, however, could not be confirmed by the CES-D study results in this 
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study. In all of the regression models, the association between CES-D and risk of 
poor adherence were not statistically significant but trend to be negative. This 
would imply that increased depressive symptoms would be associated with better 
compliance, which seems unlikely, and previous literature reported as well that 
CES-D was associated with a higher risk of poor adherence21. We conclude, 
therefore, that the weak trend toward negative associations between CES-D and 
poor adherence found in this study were probably chance events and should be 
disregarded.  
In a model considering physical functioning, mental health, age, sex 
(female), study centers, BMI and MNA-SF, it was also found that study center 
and sex have large but insignificant associations with poor adherence. Regarding 
study sites, it was found that subjects who completed study at Tufts University in 
the United States had a significant larger risk of poor adherence than subjects in 
Sweden, which agreed with exploratory results (Figure 1). The difference 
between the two study sites could be caused by many possible factors. It could 
be possible that people in the United States had a larger risk of being poor 
adherent. It could also be possible that the study investigators in Sweden 
pursued more aggressively the participants’ adherence. At this time, explanation 
for the (nonsignificant) difference is not clear. Because the design was stratified 
by study center, however, these modest differences reinforce the fact that 
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presentation of the data (and all models) should control for site, which we have 
done here.  
There also was some nonsignificant suggestion that female sex may be 
associated with a lower risk of poor adherence. Reasons for this are unknown 
and even the current scientific evidences on this association are usually 
contradictory and case-specific1. Since the association found here was also 
insignificant, it was probably true that it was caused by random error or some 
indefinable factors.  
Study Limitations 
Some limitations of this analysis should be recognized. The first and most 
important limitation is the analyses were performed based on preliminary results 
from the VIVE2 study with 112 participants records (out of 150 planned). Thus 
results must be regarded as preliminary. The lack of full adherence data raises 
the concern that analyses may be underpowered. However, since most of the 
associations found in this study were null or weak associations, the impact on the 
qualitative conclusions of this study are probably small. In a case where effects 
were more substantial or suggested a compelling overall pattern, the potential for 
type-II error would be more compelling.   
Secondly, the VIVE2 study itself was designed and organized in such a 
way that the risk of non-adherence had already been largely reduced. Subjects 
were asked to participate in a 3-time per week exercise training session so study 
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investigators have enough time to communicate and build strong binds with them. 
In fact, the general adherence levels in the VIVE2 study were very high. Subjects 
consumed 92.1% of the assigned nutrition supplements and attended 77.8% of 
the required exercise sessions. It was definitely great for the VIVE2 project but 
for this analysis, it brought up a limitation that the adherence data were not 
collected in the “natural” status. Many possible non-adhering cases might have 
been eliminated before they could occur.  
This raises a third major limitation which is the fact that reason for non-
adherence is not known. Given the design, it seems plausibly that most of the 
non-adhering events that really occurred were probably those “unavoidable” 
random events, such as family businesses and doctor’s appointments. As a 
result, the risk of poor adherence might trend to be random as well and potential 
associations eliminated by the design, but this cannot be known for sure.   
A less concerning fact was that, as stated in the result section, the sex 
distribution in this study was different from the one in the general population. In 
this study, most of the participants were male while the majority of the general 
population aged over 70 years were actually female44. The reason why this 
difference existed remained unclear. A hypothesized explanation was that it was 
more attractive for elderly men than elderly women to participate in a study 
involving long time physical activity trainings. Past studies had shown that on 
average, men have a relative higher level of physical activities than women in 
38 
 
elderly population aged over 60 years49. If this theory was true, the sex 
distribution of this study’s enrollment reflected the general acceptances of this 
nutrition supplements plus physical exercise therapy between sexes in the real 
world. In addition, no matter what caused the difference, the effect of sex was 
adjusted in 3 out of 4 regression models in this study. As a result, it probably had 
a limited impact on the study conclusion. 
Finally, the lack of depressive symptoms among subjects in the VIVE2 
study limited the ability to detect the possible association between level of 
depression and risk of poor adherence. Based on their MCS score, most of the 
people who chose to participant in this study were mentally healthy. The average 
MCS score was even higher than the national average. It could be due to the 
recruiting methods of the VIVE2 study because subjects were not randomly 
drawn from a community.  
In conclusion, this study found that in a well-organized clinical study 
among elderly people with mobility limitations, baseline SF-36 summary scores 
(PCS and MCS) were nonsignificantly associated with a slightly lower risk of poor 
adherence, while baseline CES-D score was found to have no association with 
the risk of adherence. Out of the 8 SF-36 subscales, only physical functioning 
was found to be significantly associated with a lower risk of poor exercise 
adherence. None of the subscale could predict the risk of poor product 
adherence. But these conclusions are limited by fact that the study sample is 
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relatively healthy and the trial design mitigates the risks that our analysis 
examined. 
Even though this study reported null or very weak associations of SF-36 
and CES-D scores and risk of poor adherence, it might still be true that the risk 
had already been largely reduced in this explanatory study. In the future, similar 
analyses could be done in some pragmatic clinical studies, which assess the 
effectiveness of an intervention under usual (instead of ideal) condition. In those 
pragmatic trials where the level of interaction between investigators and subjects 
was low, it might be easier to reveal the association of quality of life or level of 
depression and risk of poor adherence. If such an association exists, it might be 
a good idea to define different adherence management strategies for different 
situations so investigators could pick the most cost-efficient one based on their 
budgets and need.  
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APPENDIX I. Extra Terminologies 
Inclusion Criteria for the VIVE2 Study 
• Male and Female aged 70 years or older 
• Community dwelling 
• SPPB Score ≤ 9 
• Willingness to be randomized and com to the laboratory for 6 months 
• Body Mass Index (BMI) ≤ 35 kg/m2 
• Mini-mental state examination (MMSE) ≥ 24 
• Serum 25 (OH) D between 22.5 – 60 nmol/L 
• Having obtained his/her informed consent 
• Able to complete 400 M walk within 15 min 
Exclusion Criteria for the VIVE2 Study 
• Acute or terminal illness 
• Current regular use (more than 1 time per week) of high protein oral 
nutritional supplements (e.g. Nestlé Boost®, Exceed® etc…) 
• Current use of Vitamin D supplements (more than 800 IU per day) 
• Myocardial infarction in previous 6 months, symptomatic coronary artery 
disease, or congestive heart failure 
• Upper or lower extremity fracture in previous 6 months 
• Concentration of Hemoglobin  < 10 g/dL 
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• Estimated glomerular filtration rate (GFR) < 30 mL/min (severe decrease in 
GFR or kidney failure) 
• Uncontrolled hypertension ( > 150/90 mm Hg) 
• Neuromuscular diseases and drugs which affect neuromuscular function 
• Hormone replacement therapy 
• Insulin-dependent diabetes mellitus 
• Uncontrolled non-insulin-depend diabetes (fasting glucose > 200 mg/dL 
• Milk protein allergy 
• Major surgery in the past 6 months (requiring general anesthesia) 
• Other significant co-morbid disease that would impair ability to participate in 
the exercise-based intervention, e.g. renal failure on hemodialysis, severe 
psychiatric disorder (e.g. bipolar, schizophrenia) 
• Excessive alcohol usage (> 14 drinks per week) 
• Participation in moderate intensity physical activity > 20 minutes/week 
• Inability to communicate due to severe, uncorrected hearing loss or speech 
disorder 
• Severe visual impairment ( if it precludes completion of assessments and/or 
intervention) 
• Wheelchair bound 
• Severe progressive, degenerative neurologic disease 
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• Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, 
active inflammatory disease 
• Terminal illness with life expectancy less than 12 months, as determined by a 
physician 
• Cancer requiring treatment in the past three years, except for non-melanoma 
skin cancers or cancers that have clearly been cured or in the opinion of the 
investigator carry an excellent prognosis 
• Severe pulmonary disease, requiring either steroid pills, injections or the use 
of supplemental oxygen 
• Severe cardiac disease, including New York Heart Association (NYHA) Class 
III or IV congestive heart failure, clinically significant aortic stenosis, history of 
cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina 
• Patient who cannot be expected to comply with treatment, as decided by the 
Principal Investigator and study physician 
• Conditions not specifically mentioned above may serve as criteria for 
exclusion at the discretion of the clinical site Principal Investigator and/or 
study physician 
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APPENDIX II. Extra Tables 
TABLE A1. Baseline Descriptive Characteristics Among Randomization Groups 
Variables  
(mean, SD) 
Group A 
(nA=39) 
Group B 
(nB=37) 
Group C 
(nC=37) 
Group D 
(nD=37) 
Demographics     
Age, yr  76.6 (5.3) 77.1 (4.4) 76.8 (5.4) 79.4 (6.0) 
Female (N, %) 18 (46%) 17 (46%) 17 (46%) 17 (46%) 
Americans (N, %) 20 (51%) 20 (54%) 21 (57%) 23 (62%) 
BMI, kg/m2  28.3 (4.1) 28.6 (3.8) 27.3 (3.1) 28.3 (3.5) 
Vitamin D, nmol/L  41.5 (9.4) 42.8 (11.0) 44.4 (9.8) 42.0 (8.9) 
Baseline Tests Scores 
MNA-SF Score 13.2 (1.2) 13.6 (0.7) 13.4 (1.2) 13.1 (1.7) 
400 M Speed, m/s 0.91 (0.17) 0.93 (0.14) 0.93 (0.17) 0.86 (0.16) 
SF-36 Scores     
SF-36 Summary Scores  
PCS 45.7 (8.6) 44.8 (7.8) 45.8 (7.6) 45.4 (7.7) 
MCS 52.0 (9.4) 53.7 (8.4) 50.9 (9.7) 49.9 (9.5) 
SF-36 Subscale Scores 
Vitality 62.0(19.9) 63.6(15.3) 61.0(19.4) 59.1(19.6) 
Physical 
Functioning  
65.2(22.5) 67.6(19.0) 69.4(16.2) 66.7(20.8) 
Bodily Pain  72.6(21.9) 66.9(23.4) 66.7(22.4) 69.3(23.4) 
General Health 65.0(16.8) 66.2(18.9) 69.8(17.2) 67.5(17.2) 
Role-physical  67.3(32.8) 63.0(34.6) 65.1(33.1) 60.7(34.8) 
Role-emotional  80.0(29.2) 73.1(30.1) 73.4(29.5) 63.3(34.1) 
Social Functioning  82.9(24.2) 84.6(19.9) 83.3(21.1) 82.1(18.3) 
Mental Health  75.9(18.6) 80.2(15.4) 77.3(15.7) 77.8(17.2) 
CES-D Score 12.2 (7.3) 9.6 (5.6) 12.1 (8.2) 12.5 (7.2) 
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Table A2. Multivariate Logistic Regression Model Assessing Other Factors 
Affecting Risk of Poor Adherence 
 
Poor Exercise Adherence 
OR(95%CI) P value 
Physical Functioning 0.93 (0.88-0.97) <<0.01 
Mental Health 0.98 (0.93-1.02) 0.26 
Age 0.97 (0.84-1.10) 0.65 
Female 0.39 (0.07-1.72) 0.23 
US Center 2.97 (0.64-15.69) 0.17 
BMI 0.95 (0.74-1.19) 0.65 
MNA-SF 0.96 (0.60-1.74) 0.88 
How to read the table: every one point increase in the test scores would affect 
the odds of being categorized as Poor Adherence by a certain value. 
Abbreviations: OR, odds ratio; CI, confidence interval; SF-36, Short Form Health 
Survey.  
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